U.S. Tobacco Stock News

Earnings and contract wins shift attention to Willdan Group stock Willdan Group (WLDN) has attracted fresh attention after reporting higher fourth quarter and full year earnings, alongside securing new energy and utility contracts in California and Washington that expand its services footprint. See our latest analysis for Willdan Group. Despite the recent contract wins and stronger reported earnings, the share price has had a tough few months, with a 30 day share price return of 28% and a...

Recent share performance and business snapshot With no single headline event driving attention to Veris Residential (VRE), the recent share performance itself is the focus, as the stock shows double digit returns over the past month and past 3 months. Veris Residential is a real estate investment trust focused on Class A multifamily properties in the Northeast. It uses a technology enabled, vertically integrated platform to manage, operate, acquire, and develop its portfolio for residents and...

Corebridge Financial (CRBG) is back in focus after reporting a record US$41.7b in total premiums and deposits for 2025, alongside stronger capital and liquidity metrics that could influence how investors view the stock. See our latest analysis for Corebridge Financial. Despite the record premiums and deposits, Corebridge Financial’s recent share price performance has been weak, with a 30 day share price return of an 18.65% decline and a year to date share price return of a 16.53% decline,...

Alkermes plc recently reported that fourth‑quarter 2025 revenue slipped to US$384.55 million, with net income and earnings per share also lower year over year, while the Board confirmed CEO Richard Pops will retire in July 2026 and current COO Blair Jackson will assume the CEO role in August 2026. Alongside these results, Alkermes advanced its orexin agonist ALKS 2680 into Phase 3 trials for narcolepsy type 1, highlighting how its neuroscience pipeline is becoming increasingly central to the...

What ArriVent BioPharma’s Recent Moves Mean For Investors ArriVent BioPharma (AVBP) has been drawing attention after recent share price swings, including a 7.2% decline over the past day alongside a gain of about 7% over the past month. For a clinical stage company with no reported revenue and a net loss of US$166.308 million, those moves highlight how quickly sentiment can shift as investors weigh its cancer drug pipeline and collaborations. See our latest analysis for ArriVent...

Certara recently highlighted that its Simcyp physiologically-based pharmacokinetic modeling was accepted by the U.S. FDA in place of multiple clinical pharmacology studies to support the new drug application for asciminib (Scemblix®), an allosteric BCR::ABL1 inhibitor for Chronic Myeloid Leukemia. This decade-long modeling effort, which replaced at least ten dedicated clinical studies and informed dosing and drug-interaction decisions, underscores how biosimulation can cut development costs...

Azenta (AZTA) has drawn attention after recent share price pressure, with the stock down about 27% year to date and roughly 44% over the past year. This has prompted investors to reassess its fundamentals. See our latest analysis for Azenta. The recent pressure on Azenta’s share price, including a 1-day share price return of negative 1.98% and a 30-day share price return of negative 15.39%, sits on top of a 1-year total shareholder return of negative 44.37%. This signals that momentum has...

What triggered fresh interest in Xeris Biopharma Holdings (XERS)? Xeris Biopharma Holdings (XERS) has drawn fresh attention after reporting fourth quarter and full year 2025 results that moved from loss to profit, paired with new 2026 revenue guidance and a US$40.7 million shelf registration filing. See our latest analysis for Xeris Biopharma Holdings. Despite Xeris Biopharma Holdings posting improved earnings and setting 2026 revenue guidance, recent share price returns have been weak, with...

MarketAxess Holdings Inc. recently appointed William Quan as Chief Technology Officer, tasking him with modernizing its global technology platforms and embedding AI and advanced data capabilities across the business. By bringing in a leader with deep experience in electronic trading and AI-driven platforms from firms like Amazon Web Services, J.P. Morgan, and Deutsche Bank, MarketAxess is signaling a stronger push to enhance its bond-trading technology and product innovation. With William...

In February 2026, Marqeta, Inc. reported fourth-quarter 2025 sales of US$172.11 million with sharply reduced net losses, issued 2026 guidance calling for double-digit net revenue and gross profit growth, and filed a US$106.08 million shelf registration for 25,935,338 Class A shares tied to an employee stock plan. This combination of improving financial results, clearer growth expectations, and a sizeable employee share offering highlights how Marqeta is balancing expansion with capital and...

In early 2026, Genuine Parts Company announced plans to separate by the first quarter of 2027 into two independent, publicly traded businesses: Global Automotive and Global Industrial, each with distinct operational and capital allocation priorities. The separation is designed to give investors clearer exposure to Genuine Parts’ auto parts distribution and industrial distribution operations, which will be pursuing different growth, efficiency, and acquisition paths. Next, we’ll examine how...

In recent days, investor concerns about regional banks’ exposure to the opaque private credit market have weighed on The Bancorp, amid broader sector jitters following defaults and loan write-offs in that space. These worries come on top of earlier pressure from weaker quarterly results and a shrinking net interest margin, even as The Bancorp has built a niche in specialized fintech-focused banking and lending solutions. Next, we’ll examine how heightened worries about private credit...

In late February 2026, Starwood Property Trust, Inc. announced that its board had authorized a one-year share repurchase program of up to US$400 million, to be funded entirely from existing cash. This buyback authorization, following the company’s full-year 2025 results, signals a clear willingness to return capital while balancing earnings, leverage, and portfolio risk considerations. We’ll now examine how this sizable cash-funded buyback authorization may influence Starwood Property...

In February 2026, Xylem Inc. announced that its Board of Directors had approved a new share repurchase program, authorizing the company to buy back up to US$1.50 billion of its own stock with no expiration date. This move follows the completion of a prior authorization under which Xylem repurchased 5,200,000 shares for US$321.90 million, highlighting an ongoing preference for returning capital to shareholders alongside reinvestment in the business. We’ll now explore how this sizable,...

In late February 2026, SS&C Technologies Holdings, Inc. reported an 8.1% year-on-year revenue increase that exceeded analyst expectations and raised its full-year EPS and revenue guidance, citing strong execution and the breadth of its software and services portfolio. A few days earlier, SS&C announced a generative AI-powered sales enablement solution developed with Thornburg Investment Management, embedding advisor insights directly into CRM systems to streamline how asset managers prepare...

In its latest quarterly update, Q2 Holdings reported revenue and adjusted EBITDA above expectations, one of its strongest bookings performances with eight Tier-1 and enterprise wins, and a CEO share sale tied to tax obligations on vested Restricted Stock Units. This combination of outperformance in key operating metrics and evidence of robust demand across new and expansion deals highlights growing traction for Q2’s digital banking platform. We’ll now examine how this strong bookings quarter...

Dorchester Minerals (DMLP) recently released full year 2025 results, reporting revenue of US$152.83 million and net income of US$55.25 million, giving investors fresh data on its royalty focused energy business. See our latest analysis for Dorchester Minerals. Despite the softer full year 2025 results, Dorchester Minerals’ recent share price performance has been firm, with a 30 day share price return of 9.58% and a 90 day gain of 18.68%. However, the 1 year total shareholder return is...

Centuri Holdings, Inc. recently reported its fourth-quarter and full-year 2025 results, showing year-over-year increases in revenue and net income, and also issued full-year 2026 revenue guidance in the range of US$3.24 billion to US$3.54 billion. Alongside these earnings, Centuri confirmed it will present at the Jefferies Power, Utilities, & Clean Energy Conference 2026 in New York, underscoring its effort to communicate its growth plans and financial outlook to institutional investors. We...

In early March 2026, Lincoln Electric Holdings’ shares came under pressure after EVP, CFO & Treasurer Gabriel Bruno sold 17,473 shares in an insider transaction, following earlier strong quarterly results and optimistic guidance. This combination of an executive share sale and upbeat analyst commentary has sharpened investor focus on how leadership actions align with the company’s longer-term outlook and fundamentals. We’ll now examine how the CFO’s recent insider sale could influence...

Why Brixmor Property Group Stock Is On Investors’ Radar Brixmor Property Group (BRX) has drawn fresh attention after recent trading left the stock with a month return of 6.2% and a past 3 months move of 21.9%, prompting closer scrutiny of the REIT’s fundamentals. See our latest analysis for Brixmor Property Group. At a share price of US$30.07, Brixmor’s recent 6.2% 1 month and 21.9% 3 month share price returns contrast with some softer short term moves. Its 1 year and multi year total...

DT Midstream (DTM) has drawn fresh attention after reporting 17% year-over-year adjusted EBITDA growth for 2025, expanding its Pipeline segment to 70% of the business and raising its quarterly dividend by 7.3%. See our latest analysis for DT Midstream. The latest operational update seems to line up with recent market interest, with a 30 day share price return of 10.1% and a 90 day share price return of 17.5%. The 1 year total shareholder return of 65.6% and 3 year total shareholder return of...

What is driving interest in Acuity right now? Acuity (AYI) has caught investor attention after recent share price weakness, with the stock showing negative returns over the past week, month, past 3 months and year to date, despite positive multi year total returns. See our latest analysis for Acuity. At a share price of US$275.42, Acuity’s short term share price return has been weak, with the 30 day move of 16.13% decline adding to a 26.23% year to date fall, while longer term total...

Bicara Therapeutics (BCAX) is back on investor watch after reporting a 54% overall response rate for its FICERA program, alongside a recent public equity raise that supports continued clinical development and early commercial planning. See our latest analysis for Bicara Therapeutics. The recent FICERA update and capital raise come after a 20.25% 1 month share price return and a 12.76% year to date share price return. The 1 year total shareholder return of 11.60% suggests momentum is starting...

Astrana Health recently reported its fourth-quarter and full-year 2025 results, with revenue rising to US$950.53 million for the quarter and US$3.18 billion for the year, a return to quarterly profitability and continued full-year profit, while also announcing delayed filing of its 2025 Form 10-K due to a material internal-control weakness that did not change the reported figures. Alongside this, the company issued 2026 revenue guidance of US$900 million–US$1.00 billion for the first quarter...